Investigating the role of a lipid transporter in colorectal cancer inflammation
The Role of Lipid Transporter MFSD2A in the Resolution of Colorectal Cancer-associated Inflammation: Implications for New Therapeutic Strategies
This study is trying to understand how a specific lipid transporter affects inflammation in colorectal cancer to see if it can lead to new treatments for patients with this condition.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 15 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | IRCCS San Raffaele Academic / other |
| Locations | 1 site (Milan) |
| Trial ID | NCT06071598 on ClinicalTrials.gov |
What this trial studies
This observational study examines the role of the lipid transporter MFSD2A in the resolution of inflammation associated with colorectal cancer (CRC). It focuses on understanding how inflammation contributes to tumor promotion in CRC patients, particularly those with inflammatory bowel diseases. The study involves analyzing surgical specimens from CRC-affected patients, stratified by tumor stage, to uncover potential mechanisms that could lead to new therapeutic approaches targeting cancer-associated inflammation.
Who should consider this trial
Good fit: Ideal candidates for this study are patients diagnosed with colorectal cancer, particularly those with varying tumor stages.
Not a fit: Patients who have undergone previous intestinal resection or are taking specific medications like trace elements or hypolipemiants in the last three months may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to the development of novel therapies that effectively manage inflammation in colorectal cancer without compromising the body's natural defenses.
How similar studies have performed: While the connection between inflammation and cancer is well-established, this specific approach focusing on MFSD2A is novel and has not been extensively tested in previous studies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: - 15 CRC-affected patients stratified according to tumor stage (T0/T1-T4, M0/M1, N0/N1/N2) Exclusion Criteria: Patients: * taking trace elements, hypolipemiants in the previous 3 months * undergone previous intestinal resection
Where this trial is running
Milan
- IRCCS Ospedale San Raffaele — Milan, Italy (Recruiting)
Study contacts
- Study coordinator: Federica Ungaro
- Email: ungaro-federica@hsr.it
- Phone: 0226437864
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.